Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
News|Articles|December 5, 2025
Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025
Author(s)Kyle Doherty
Fact checked by: Ashling Wahner
Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.
Advertisement
Advertisement
With the upcoming
Related to this article
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Advertisement
Advertisement